SCYNEXIS, Inc. Convertible Debt
SCYNEXIS, Inc. (SCYX) had Convertible Debt of $0 as of 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ConvertibleDebt · last filed 2025-11-05
- 2025-09-30: Convertible Debt $0.00.
- 2025-06-30: Convertible Debt $0.00.
- 2025-03-31: Convertible Debt $0.00.
- 2024-12-31: Convertible Debt $13.69M.
| Period end | Convertible Debt |
|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 |
| 2024-12-31 | $13.69M 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |